<DOC>
	<DOCNO>NCT01608217</DOCNO>
	<brief_summary>This phase II , randomize , placebo-controlled , double-blind , parallel-group , multicentre study efficacy safety low dose delta-9-THC behavioural disturbance pain patient mild severe dementia , add analgesic treatment acetaminophen . It hypothesize Namisol® lead behavioural disturbance placebo , add analgesic treatment acetaminophen , measure change Neuropsychiatric Inventory ( NPI ) score , three week treatment period . It expect due , primarily , psychoactive effect Namisol® secondary reduction pain sensation ( measure VRS PACSLAC-D ) . It expect reduction NPS positively affect quality life lead well functioning daily living .</brief_summary>
	<brief_title>Delta-THC Dementia</brief_title>
	<detailed_description>There high prevalence behavioural disturbance ( NPS ) person dementia . Persistent pain complaint cause NPS . Unfortunately , lack appropriate drug treat problem . This positive suggestion preliminary clinical study THC NPS directly fuel study present . This phase II study efficacy safety Namisol® ( tablet THC ) behavioural disturbance , agitation , aggression motor disturbance dementia patient evaluate . Secondary study objective : 2 . To evaluate efficacy Namisol® secondary outcome measure , quality life function daily activity . 3 . To evaluate safety Namisol® assess physical examination , effect cognitive function adverse event monitoring . 4 . For subgroup subject suffer pain : evaluate efficacy Namisol® pain intensity It hypothesize Namisol® lead reduction behavioural disturbance placebo , add analgesic treatment acetaminophen , measure change Neuropsychiatric Inventory ( NPI ) score , three week treatment period . It expect due , primarily , psychoactive effect Namisol® secondary reduction pain sensation ( measure VRS PACSLAC-D ) . It expect reduction NPS positively affect quality life lead well functioning daily living This randomized placebo-controlled double-blind parallel-group multicentre study . Subjects appear fulfill eligibility criterion inform study . After sign informed consent subject and/or caregiver , screen visit take place . Subjects eligible participation enter wash-out period , discontinuation analgesic medication ( applicable ) . Subjects randomly allocate receive one two intervention ( Namisol® 1.5 mg + acetaminophen 1000 mg three time daily , placebo + acetaminophen 1000 mg three time daily ) double-blind intervention period three week . After two week primary outcome measure ( NPI ) assess telephone interview caregiver . Subjects visit site twice ( baseline three week treatment ) assessments outcome parameter , include NPI . For purpose compliance safety , weekly phone call , perform researcher . After completion period subject 's analgesic treatment restart ( applicable ) . After follow phase two week , subject contact telephone assessment adverse event .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subject possible probable dementia , type Alzheimer , vascular mixed type dementia , accord criterion NINCDSADRDA/NINCDSAIREN base expert panel decision . Clinical Dementia Rating ( CDR ) score 1 3 ( mild severe dementia ) . Age ≥ 40 year . Clinically relevant behavioral disturbance exist least one month prior screen , define score ≥ 10 NPI , include presence domain agitation/aggression motor disturbance . Women postmenopausal phase . Availability informal formal caregiver , touch subject least twice week . Informed consent subject subject 's informal caregiver . If applicable : subject willing stop his/her pain medication , duration study . Exclusion criterion : Dementia AD , VaD AD/VaD Major psychiatric disorder : major depression accord DSM IV within 6 month prior randomization , history psychosis mania , current hallucination and/or delirium , current suicidal ideation major anxiety disorder . History , current drug abuse . Current alcohol abuse unwillingness use 2 alcoholic consumption daily raise gammaglutamine transpeptidase alkaline phosphatase . Clinical biochemical evidence liver disease ( ALT AST ≥ twice upper limit normal ) know allergy acetaminophen . Severe ( and/or unstable ) concomitant intercurrent illness , seizure , arrhythmias require drug beta blocker digoxin ( except sinus arrhythmia atrial fibrillation ) , unstable angina pectoris , heart failure NYHA III IV , severe concomitant illness require treatment change . Known suspect sensitivity cannabinoids . Lactosis intolerance . Frequent fall due orthostatic hypotension . Use tricyclic antidepressant ( TCA ) , fluoxetine and/or carbamazepine . Changes dosage antipsychotic , benzodiazepine cholinesterase inhibitor within 2 week prior intervention . Participation study descriptive 'Parelsnoer ' study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Behavioural disturbance</keyword>
	<keyword>Pain</keyword>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's dementia</keyword>
	<keyword>Vascular dementia</keyword>
	<keyword>THC</keyword>
	<keyword>Cannabis</keyword>
</DOC>